gp100 (280-288)

gp100 (280-288) is a synthetic peptide fragment derived from the human glycoprotein 100 (gp100), a melanocyte differentiation antigen that is highly expressed in melanoma cells. As a well-characterized epitope, this nonapeptide corresponds to amino acids 280 through 288 of the full-length gp100 protein. Its defined sequence and immunological relevance have made it a valuable tool for investigating antigen presentation, T cell recognition, and immune response mechanisms in cancer immunology and peptide-based research. The peptide's precise structure enables researchers to explore molecular interactions at the interface of tumor antigens and the adaptive immune system, supporting a wide range of experimental applications in both basic and translational studies.

Antigen presentation studies: The gp100 (280-288) peptide is widely utilized to examine the process of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules, particularly HLA-A2. By serving as a model epitope, it allows for the detailed analysis of peptide-MHC binding affinity, stability, and the subsequent activation of cytotoxic T lymphocytes (CTLs). Researchers employ this peptide to dissect the molecular determinants that govern immune recognition of tumor antigens, enabling the identification of key factors that influence the efficacy of antigen presentation in vitro.

T cell activation assays: In immunological research, the gp100 (280-288) fragment is frequently applied in functional assays designed to assess the activation, specificity, and cytotoxic potential of T cells. By pulsing antigen-presenting cells with this peptide, investigators can evaluate T cell receptor (TCR) engagement, cytokine production, and proliferation responses. These studies are essential for characterizing immune cell dynamics in response to tumor-associated antigens, supporting the development of novel strategies for immunomodulation and adoptive cell transfer research.

Epitope mapping and validation: The defined sequence of the gp100 (280-288) peptide makes it a critical reagent for epitope mapping studies. By systematically testing its recognition by T cells from different donors or experimental models, researchers can validate the immunodominance and cross-reactivity of this epitope. Such investigations contribute to a deeper understanding of antigenic determinants within the gp100 protein and facilitate the rational design of synthetic peptides for immunological research and vaccine development.

Peptide-MHC multimer generation: The gp100 (280-288) sequence is commonly employed in the synthesis of peptide-MHC multimers, such as tetramers or pentamers, which are used to detect and isolate antigen-specific CD8+ T cells. These multimers enable precise monitoring of immune responses in experimental systems, allowing for the enumeration and phenotypic analysis of T cell populations that recognize melanoma-associated antigens. The use of this peptide in multimer technology enhances the resolution and sensitivity of immunological assays, supporting advanced research in tumor immunology.

Immunogenicity assessment: Researchers utilize the gp100 (280-288) peptide to evaluate the immunogenic potential of tumor-associated epitopes in preclinical models. By incorporating it into in vitro or ex vivo assays, scientists can measure the frequency and functional capacity of antigen-specific T cells generated in response to peptide stimulation. These studies inform the selection and optimization of candidate epitopes for further investigation, advancing the understanding of immune recognition in the context of melanoma and other malignancies.

1. TMEM16F and dynamins control expansive plasma membrane reservoirs

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes